One unifying element of this program project is the use of Mycoplasma pulmonis-infected mice and rats as a model of chronic airway inflammation. All four projects will use this model to some extent in the proposed research. A small animal core will be established to meet this need. The ore has three main functions: (i) to standardize the infection procedures and handling of pathogen-free and infected mice and rats in the barrier facility; (ii) to maximize the efficiency and economy of housing and handling pathogen-free and infected animals; and (iii) to make pathogen-free and M. pulmonis-infect animals or tissues from these animals readily available to all of the investigators. The core staff will use tested stocks of M. pulmonis to ensure reproducible results and to minimize variability. The core staff will be responsible for husbandry and monitoring of pathogen-free and infected animals in the barrier facility, including the routine measurement of body weight, maintenance of sentinel animals, and periodic serological analyses. The core staff will also assist with some aspects of tissue harvesting, for example, bronchoalveolar lavage, flow cytometry, and tissue removal and fixation. Lastly, the core will assist in the breeding, colony management, and genetic analysis of various mutant animals stocks that will be used in the four projects. The core will build on an existing infrastructure that is already being used to generate M. pulmonis-infected mice and rats on a small scale. Centralizing and expanding the currently limited scope of the infection and maintenance process will avoid unnecessary replication of resources in the four projects. It will also ensure that common procedures are used by all of the groups and will, therefore, facilitate the exchange of information and foster collaborative interactions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL024136-25
Application #
6781172
Study Section
Project Start
2003-07-01
Project End
2004-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2003
Total Cost
$142,703
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Ma, Qiaoli; Dieterich, Lothar C; Ikenberg, Kristian et al. (2018) Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Sci Adv 4:eaat4758
Kim, Minah; Nitschké, Maximilian; Sennino, Barbara et al. (2018) Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res 78:922-937
Nitschké, Maximilian; Bell, Alexander; Karaman, Sinem et al. (2017) Retrograde Lymph Flow Leads to Chylothorax in Transgenic Mice with Lymphatic Malformations. Am J Pathol 187:1984-1997
Shepherd, Joanna; Fisher, Matthew; Welford, Abigail et al. (2017) The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget 8:95648-95661
Baluk, Peter; Yao, Li-Chin; Flores, Julio C et al. (2017) Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight 2:
Pinkard, Henry; Corbin, Kaitlin; Krummel, Matthew F (2016) Spatiotemporal Rank Filtering Improves Image Quality Compared to Frame Averaging in 2-Photon Laser Scanning Microscopy. PLoS One 11:e0150430
Sen, Debasish; Jones, Stephen M; Oswald, Erin M et al. (2016) Tracking the Spatial and Functional Gradient of Monocyte-To-Macrophage Differentiation in Inflamed Lung. PLoS One 11:e0165064
Greenland, John R; Wong, Charissa M; Ahuja, Rahul et al. (2016) Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts. Transplantation 100:2090-8
Huang, Jennifer L; Woolf, Adrian S; Kolatsi-Joannou, Maria et al. (2016) Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases. J Am Soc Nephrol 27:69-77
Caughey, George H (2016) Mast cell proteases as pharmacological targets. Eur J Pharmacol 778:44-55

Showing the most recent 10 out of 593 publications